MCL1 and colorectal carcinoma: Although the accumulation of nuclear MCL1 drives chemoresistance, this relocation process sensitizes cells to apoptosis driven by selective inhibition of Bcl-xL, advocating for combining Bcl-xL selective inhibitors with DNA damaging agents in patients with CRC.